Biomerica Inc. Celebrates a Major Milestone with UAE Approval

In a significant development for Biomerica, Inc., the United Arab Emirates Ministry of Health and Prevention has granted approval for the company’s Fortel Ulcer Test for home use. This approval marks a pivotal moment for Biomerica, a global medical company dedicated to improving the lives of individuals with chronic illnesses while reducing healthcare costs. The Fortel Ulcer Test, a 10-minute diagnostic tool, detects antibodies to Helicobacter pylori (H. pylori), a bacterium that affects 41% of the UAE population and is linked to approximately 80% of gastric cancer cases.

The approval is expected to bolster Biomerica’s presence in the Middle East market, following the successful launch of their EZ Detect™ C test. The Fortel Ulcer Test will be distributed through UAE-based partners and made available at pharmacies, clinics, and online platforms, making it easily accessible to the public. This move is particularly significant given that H. pylori is classified as a Class 1 carcinogen by the World Health Organization (WHO) and can lead to serious complications, including peptic ulcers and gastric cancer, in up to 20% of infected individuals if left untreated.

The news of the UAE’s approval has had an immediate and positive impact on Biomerica’s stock performance. On August 14, 2025, Biomerica’s stock soared following the announcement, reflecting investor confidence in the company’s growth prospects. The stock’s rise is a testament to the market’s recognition of the potential impact of the Fortel Ulcer Test in addressing a significant public health issue in the UAE.

Biomerica, Inc., listed on the Nasdaq under the ticker BMRA, operates in the Health Care Equipment & Supplies sector. With a market capitalization of approximately $8.94 million and a close price of $3.51 on August 13, 2025, the company has shown resilience despite fluctuations in its stock price over the past year. The 52-week high was $10.16 on January 15, 2025, while the low was $2.08 on December 22, 2024.

This approval not only enhances Biomerica’s product portfolio but also aligns with its mission to provide innovative diagnostic solutions that improve patient outcomes and reduce healthcare costs. As the company continues to expand its reach in the Middle East, the Fortel Ulcer Test is poised to play a crucial role in early detection and management of H. pylori infections, ultimately contributing to better health outcomes for millions.

In summary, the UAE’s approval of Biomerica’s Fortel Ulcer Test for home use is a landmark achievement for the company, promising to strengthen its market position and drive future growth. With its focus on addressing chronic illnesses and improving healthcare accessibility, Biomerica is well-positioned to make a lasting impact in the global healthcare landscape.